These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12823345)

  • 1. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
    Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
    Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.
    Galmarini CM; Cros E; Thomas X; Jordheim L; Dumontet C
    Haematologica; 2005 Dec; 90(12):1699-701. PubMed ID: 16330448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia.
    Galmarini CM; Graham K; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Mackey JR; Dumontet C
    Blood; 2001 Sep; 98(6):1922-6. PubMed ID: 11535530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential mechanisms of resistance to cytarabine in AML patients.
    Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
    Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
    Galmarini CM; Thomas X; Calvo F; Rousselot P; Rabilloud M; El Jaffari A; Cros E; Dumontet C
    Br J Haematol; 2002 Jun; 117(4):860-8. PubMed ID: 12060121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.
    Suzuki K; Sugawara T; Oyake T; Uchiyama T; Aoki Y; Tsukushi Y; Onodera S; Ito S; Murai K; Ishida Y
    Leuk Res; 2007 Oct; 31(10):1343-9. PubMed ID: 17350683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine.
    Galmarini CM; Cros E; Graham K; Thomas X; Mackey JR; Dumontet C
    Haematologica; 2004 May; 89(5):617-9. PubMed ID: 15136231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
    Veuger MJ; Honders MW; Willemze R; Barge RM
    Eur J Haematol; 2002 Sep; 69(3):171-8. PubMed ID: 12406011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.
    Jaramillo AC; Bergman AM; Comijn EM; Jansen G; Kaspers GJL; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1346. PubMed ID: 32727269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia.
    Månsson E; Liliemark E; Söderhäll S; Gustafsson G; Eriksson S; Albertioni F
    Leukemia; 2002 Mar; 16(3):386-92. PubMed ID: 11896543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
    Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
    Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
    Flasshove M; Strumberg D; Ayscue L; Mitchell BS; Tirier C; Heit W; Seeber S; Schütte J
    Leukemia; 1994 May; 8(5):780-5. PubMed ID: 7514246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
    Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
    Hubeek I; Stam RW; Peters GJ; Broekhuizen R; Meijerink JP; van Wering ER; Gibson BE; Creutzig U; Zwaan CM; Cloos J; Kuik DJ; Pieters R; Kaspers GJ
    Br J Cancer; 2005 Dec; 93(12):1388-94. PubMed ID: 16333246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia.
    Veuger MJ; Honders MW; Landegent JE; Willemze R; Barge RM
    Blood; 2000 Aug; 96(4):1517-24. PubMed ID: 10942400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
    Lamba JK; Crews K; Pounds S; Schuetz EG; Gresham J; Gandhi V; Plunkett W; Rubnitz J; Ribeiro R
    J Pharmacol Exp Ther; 2007 Dec; 323(3):935-45. PubMed ID: 17855478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.